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vención Coronaria Percutánea). La medida de efectividad fue la tasa de éxitos clíni-
cos sin eventos adversos cardiovasculares mayores a 3 años. El costo y la
efectividad los tratamientos se obtuvo del seguimiento clínico de la cohorte de
n230 pacientes en el Hospital de Cardiología del IMSS seguidos por 3 años. Se
utilizó la técnica de micro-costeo, los costos provienen de bases de costos institu-
cionales (2010). Los resultados están expresados en dólares americanos (USD) del
2010 (tipo de cambio MX$12.63: $1 USD). Se empleó una tasa de descuento del 5%.
Además del modelo determinístico, se realizó un análisis de sensibilidad proba-
bilístico y se estimó la curva de aceptabilidad. RESULTADOS: El 59.3% de los paci-
entes de la cohorte utilizó BMS y el 40.87% DES. El grupo con DES mostró los may-
ores costos promedio por paciente USD$16,635 comparado con BMS USD$13,432.
Las efectividades DES encontradas fueron de 88% y las de BMS 74%. La RCE fue de
USD$15,263 en el caso de DES y de USD$22,480 con BMS. El DES se ubicó como la
alternativa costo-efectiva y dominante frente al empleo del BMS. La curva de acept-
abilidad muestra que el tratamiento de DES se ubicó como la alternativa costo-
efectiva independientemente de la Disponibilidad a Pagar por parte de la
institución. CONCLUSIONES: Los resultados del análisis realizado sugieren que
DES es una alternativa de tratamiento intervencionista de revascularización con
mejores resultados en salud, y que también representa una alternativa costo ahor-
radora respecto a BMS.
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OBJECTIVES: To develop a cost-effectiveness and a budget impact analysis of Ri-
varoxaban in the prevention of thromboembolic events in patients performing hip
and knee arthroplasty in comparison with no treatment under the Brazilian private
health care system perspective.METHODS:A decision tree analysis was developed
for the first 90 days, considering the occurrence of Deep Venous Thrombosis, Pul-
monary Embolism and thromboembolic events, followed by a Markov model, for
Post Thrombotic Syndrome and Thrombotic Pulmonary Hypertension. The time
horizon of the analysis was 5 year. The cycle duration was 1 year and the corre-
sponding epidemiological and efficacy data were obtained from a critical appraisal
of the scientific literature. Unit costs for drugs, procedures, materials and daily
hospital were obtained from Kairos Magazine (Maximum price consumers
18%ICMS), Hierarchical Brazilian Classification of Medical Procedures (CBHPM 5th
edition), Simpro Magazine Maximum price consumers 18% ICMS) and search UNI-
DAS 2008, respectively. A budget impact analysis was developed considering an
increase of 10% per year in market share of Rivaroxaban. RESULTS: Total costs
associated with Rivaroxaban and no treatment, considering the indication for knee
arthroplasty, were BRL363 (US$214) and BRL1,040 (US$612), respectively. And con-
sidering the indication for hip arthroplasty, were BRL332 (US$195) and BRL462
(US$272), respectively. Rivaroxaban reduces the number of all thromboembolic
events in 0.0793 and 0.0246, for knee and hip arthroplasty, respectively. Rivaroxa-
ban treatment is more effective and cheaper than no treatment in both indications
(dominant). The high cost associated with no treatment patient is due to the high
number of events in this group. The budget impact analysis estimated an economy
of BRL206,165 (US$121,274) and BRL104,351 (US$61,383) for knee and hip indication,
respectively, in 5 years. CONCLUSIONS: By this pharmacoeconomic analysis, the
treatment with Rivaroxaban, shown to reduce treatment costs and events com-
pared with no treatment.
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OBJECTIVES: To develop a cost-effectiveness and a budget impact analysis of Ri-
varoxaban in the prevention of thromboembolic events in patients performing hip
and knee arthroplasty in comparison with Enoxaparin under the Brazilian private
health care system perspective.METHODS:A decision tree analysis was developed
for the first 90 days, considering the occurrence of Deep Venous Thrombosis, Pul-
monary Embolism and thromboembolic events, followed by a Markov model, for
Post Thrombotic Syndrome and Thrombotic Pulmonary Hypertension. The time
horizon of the analysis was 5 year. The cycle duration was 1 year and correspond-
ing epidemiological and efficacy data were obtained from a critical appraisal of the
scientific literature. The outcomes were expressed as the incremental number of
all thromboembolic events. The analysis considered only direct medical costs. Unit
costs for drugs, procedures, materials and daily hospital were obtained from Kairos
Magazine (Maximum price consumers 18% ICMS), Hierarchical Brazilian Classifi-
cation of Medical Procedures (CBHPM 5thedition), Simpro Magazine (Maximum
price consumers 18%ICMS) and UNIDAS 2008, respectively. A budget impact anal-
ysis was developed considering an increase of 10% per year in market share of
Rivaroxaban. RESULTS: Total costs associated with Rivaroxaban and Enoxaparin,
considering the indication for knee arthroplasty, were BRL363 (US$214) and BRL632
(US$372), respectively. Rivaroxaban reduces the number of all thromboembolic
events in 0.0167. Rivaroxaban treatment is more effective and cheaper than Enoxa-
parin treatment (dominant). Total costs associated with Rivaroxaban and Enoxa-
parin, considering the indication for hip arthroplasty, were BRL332 (US$195) and
BRL468 (US$275), respectively. The number of all thromboembolic events was the
same. Rivaroxaban treatment is cheaper with same efficacy. The budget impact
analysis estimated an economy of BRL98,810 (US$58,124) and BRL184,630
(US$108,606) for knee and hip indication, respectively, in 5 years. CONCLUSIONS:
By this pharmacoeconomic analysis, the treatment with Rivaroxaban, shown to
reduce treatment costs and events compared with Enoxaparin.
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OBJECTIVES: To evaluate the cost-effectiveness of prasugrel versus clopidogrel in
patients with acute coronary syndromes (ACS) undergoing percutaneous coronary
intervention (PCI) from the public healthcare payer perspective in Mexico.
METHODS: The alternatives were prasugrel (loading dose 60 mg, maintenance
dose 10 mg daily) versus clopidogrel (loading dose 300 mg, maintenance dose 75 mg
daily). A Markov model was developed. Only direct medical care costs were con-
sidered for one year. The efficacy measure was a composite of the death from
cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke and stent
thrombosis reported in the trial directly comparing prasugrel and clopidogrel (TRI-
TON TIMI-38). Three types of populations were evaluated separately; overall, pa-
tients with diabetes mellitus, and the subset of diabetics treated with insulin. Care
costs were derived from medical records, and the costs of drugs were assumed to
be the same. Costs and the model were validated by experts. RESULTS: According
to the model prasugrel had fewer events in the three types of populations evalu-
ated over a 12 month time horizon. The number of events; death from cardiovas-
cular causes, nonfatal myocardial infarction-stroke and stent thrombosis avoided
by 10,000 patients were distributed as follows: overall population, 31, 650 and 147,
diabetics, 92, 1363 and 203, diabetics on insulin, 174, 2531 and 499. The average cost
per patient (2010 Mexican pesos) treated with prasugrel was lower compared with
clopidogrel, for the overall population (MXN$ 69,972 vs. MXN$ 82,991), diabetics
(MXN$79,971 vs. MXN$ 105,756) and diabetics treated with insulin (MXN$ 85,750 vs.
MXN$ 137,144). CONCLUSIONS: Results from the present analysis suggest that the
use of prasugrel (instead of clopidogrel) in patients with ACS undergoing PCI rep-
resents a more effective strategy at a lower cost (dominant strategy), a cost-saving
alternative for institutions of public healthcare in Mexico.
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OBJECTIVES: To develop a cost-effectiveness and a budget impact analysis of Ri-
varoxaban in the prevention of thromboembolic events in patients performing hip
and knee arthroplasty in comparison with Dabigatran under the Brazilian private
health care system perspective.METHODS:A decision tree analysis was developed
for the first 90 days, considering the occurrence of Deep Venous Thrombosis, Pul-
monary Embolism and thromboembolic events, followed by a Markov model, for
Post Thrombotic Syndrome and Thrombotic Pulmonary Hypertension. The time
horizon of the analysis was 5 year. The cycle duration was 1 year and correspond-
ing epidemiological and efficacy data were obtained from a critical appraisal of the
scientific literature. The outcomes were expressed as the incremental number of
all thromboembolic events. The analysis considered only direct medical costs. Unit
costs for drugs, procedures, materials and daily hospital were obtained from Kairos
Magazine (Maximum price consumers 18%ICMS), Hierarchical Brazilian Classifica-
tion of Medical Procedures (CBHPM 5thedition), Simpro Magazine (Maximum price
consumers 18%ICMS) and UNIDAS 2008, respectively. A budget impact analysis
was developed considering an increase of 10% per year in market share of
Rivaroxaban. RESULTS: Total costs associated with Rivaroxaban and Dabigatran,
considering the indication for knee arthroplasty, were BRL363 (US$214) and BRL371
(US$218), respectively. The number of all thromboembolic events was the same.
Rivaroxaban treatment is cheaper with same efficacy. Total costs associated with
Rivaroxaban and Dabigatran, considering the indication for hip arthroplasty, were
BRL332 (US$195) and BRL485 (US$285), respectively. Rivaroxaban reduces the num-
ber of all thromboembolic events in 0.0140. Rivaroxaban treatment is more effec-
tive and cheaper than Dabigatran treatment (dominant). The budget impact anal-
ysis estimated an economy of BRL3,894 (US$2,291) and BRL150,642 (US$88,613) for
knee and hip indication, respectively, in 5 years.CONCLUSIONS: By this pharmaco-
economic analysis, the treatment with Rivaroxaban, shown to reduce treatment
costs and events compared with Dabigatran.
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